Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial

BACKGROUND: After two studies reporting response rates higher than 70% in HER2-positive metastatic breast cancer with weekly trastuzumab and vinorelbine, we planned a phase 2 study to test activity of the same combination, with trastuzumab given every 3 weeks. METHODS: Patients with HER2-positive me...

Descripción completa

Detalles Bibliográficos
Autores principales: De Maio, Ermelinda, Pacilio, Carmen, Gravina, Adriano, Morabito, Alessandro, Di Rella, Francesca, Labonia, Vincenzo, Landi, Gabriella, Nuzzo, Francesco, Rossi, Emanuela, Silvestro, Pasqualina, Botti, Gerardo, Di Bonito, Maurizio, Curcio, Maria Pia, Formichelli, Franca, La Vecchia, Franca, Staiano, Maria, Maurea, Nicola, D'Aiuto, Giuseppe, D'Aiuto, Massimiliano, Thomas, Renato, Signoriello, Giuseppe, Perrone, Francesco, de Matteis, Andrea
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2007
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1832208/
https://www.ncbi.nlm.nih.gov/pubmed/17374151
http://dx.doi.org/10.1186/1471-2407-7-50

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1832208/
https://www.ncbi.nlm.nih.gov/pubmed/17374151
http://dx.doi.org/10.1186/1471-2407-7-50

Ejemplares similares